Point-of-Care Diagnostics Market

Point-of-Care Diagnostics Market Outlook 2026 to 2033

The global point-of-care diagnostics market is projected to expand from USD 24.5 billion in 2026 to USD 36.5 billion by 2033, registering an annualised growth rate of 5.9% over the forecast period. The point-of-care diagnostics market growth projections represents a structurally stronger and more diversified market base. The era of COVID-19-led volatility has transitioned into a more balanced growth trajectory anchored in chronic disease management, decentralized healthcare delivery and technological integration across diagnostic platforms.

Point-of-care diagnostics market growth is influenced by sophisticated convergence of microfluidics, AI-driven interpretation, as well as high-speed connectivity. While infectious disease testing remains a dominant pillar, the long-term expansion is fueled by the management of chronic conditions such as, diabetes and cardiovascular disease. In regions like North America and Europe, the focus is on reducing hospital readmissions through home monitoring, whereas in emerging economies across Asia-Pacific, point-of-care diagnostics are serving as the primary infrastructure for healthcare delivery in underserved rural pockets.

North America remains a prominent market, driven by reimbursement depth, rapid technology adoption, and a favorable regulatory environment. Asia-Pacific is witnessing ample growth opportunities where rising primary healthcare investments and rural diagnostic penetration programs are reshaping demand. Point-of-care diagnostics market is being bolstered by the convergence of portable diagnostics, AI-enabled diagnosis, smartphone connectivity and the policy push towards value-based care models.

Point-of-Care Diagnostics Market Scenario & Strategic Insights

The point-of-care diagnostics market has entered into a maturity phase and in the coming years growth projections is estimated to witness a downward trend. Substantial COVID-driven revenues have normalized in past years, yet the installed base of devices and consumer familiarity with rapid tests have altered healthcare delivery models. Governments and healthcare systems that invested heavily in decentralized testing infrastructure are now repurposing these networks for influenza, RSV, cardiac markers, and metabolic monitoring.

Rising healthcare costs, clinician shortages, and hospital overcrowding are accelerating the shift toward near-patient testing. In the United States, policy directives promoting domestic medical manufacturing resilience, reinforced by executive-level emphasis on supply chain localization, have further encouraged investments in POC device manufacturing. Similarly, European healthcare reforms emphasizing early diagnosis and chronic disease prevention are supporting steady adoption. Rather than explosive growth, clinically integrated expansion supported by technological differentiation.

Recent executive orders under the U.S. administration have aimed at streamlining the FDA’s de novo and 510(k) pathways, prioritizing American-made diagnostic hardware and reducing the regulatory red tape that previously slowed the transition of complex molecular tests to CLIA-waived status. These policy shifts are designed to foster domestic innovation and lower the cost of entry for startups, though they simultaneously demand higher self-regulation and rigorous quality control from manufacturers as federal oversight becomes streamlined.

Attribute	2026	2033	CAGR (2026 – 2033)
Market Size	USD 24.5 Billion	USD 36.5 Billion	5.9%

Point-of-Care Diagnostics Market Trends

1. Decentralization of Diagnostics into Primary and Home Settings transforming Point-of-Care Diagnostics market

Healthcare systems are moving away from centralized laboratories toward distributed diagnostic ecosystems. Pharmacies, urgent care clinics and even employer health centers are adopting compact analyzers capable of delivering lab-quality results in minutes. For example, Abbott expanded its rapid molecular testing portfolio to include respiratory panels beyond COVID-19, leveraging its existing device footprint. The shift reduces patient wait times and lowers systemic costs, two metrics payers increasingly prioritize and benefiting the growth of point-of-care diagnostics market.

Major retail players like CVS Health and Walgreens have transformed their business models to become primary diagnostic destinations. The test-and-treat model has become standardized, where a patient can receive a POC flu or strep test and a prescription in a single 20-minute visit. This shift is siphoning volume away from traditional hospital outpatient labs and into highly efficient high-volume retail sector.

• AI-Integrated and Digitally Connected Platforms influencing Point-of-Care Diagnostics market

AI is increasingly embedded into POC devices to enhance result interpretation, reduce false positives and provide clinical decision support. Connectivity with electronic health records (EHR) is becoming standard, companies are integrating cloud dashboards to enable remote monitoring for chronic diseases like diabetes and cardiovascular conditions. Roche and Siemens Healthineers have invested heavily in digital ecosystems that allow real-time data sharing between clinicians and patients benefiting them to increase their presence in point-of-care diagnostics market.

Further, Abbott began deploying Explainable AI interfaces that do more than give a positive/negative result, they provide a confidence score and guided next steps. This trend mitigates the risk of operator error. This digital layer is a critical differentiator, transforming POC devices from standalone tools into nodes within a broader health data infrastructure.

• Expansion of Multiplex and Molecular Testing to bolster position in Point-of-Care Diagnostics market

Multiplex POC testing capable of detecting multiple pathogens or biomarkers simultaneously is gaining traction in the point-of-care diagnostics market. Post-pandemic awareness has accelerated demand for comprehensive respiratory panels rather than single-analyte tests. Recent regulatory clearances in the U.S. and EU for compact PCR-based systems underscore this trend. Molecular POC testing used to be expensive for widespread use, is becoming cost-competitive due to miniaturization and cartridge innovation. This has expanded POC applicability beyond infectious diseases into oncology markers and antimicrobial resistance detection.

Segment & Category Analysis in Point-of-Care Diagnostics Market

The point-of-care diagnostics market has been categorised based on product type, sample type, technology, prescription type and end user

Point-of-Care Diagnostics Market Outlook by Product Type

• Glucose Monitoring Devices
• Infectious Disease Testing Devices
• Cardiometabolic Testing Devices
• Pregnancy and Fertility Testing Devices
• Coagulation Testing Devices
• Urinalysis Testing Devices
• Hematology Testing Devices

Glucose monitoring devices is estimated to account for 43% of the revenue share in point-of-care diagnostics market due to the global diabetes burden. Continuous glucose monitoring systems are blurring the lines between traditional POC and wearable medical technology, especially in developed markets. The replacement cycle and recurring consumables generate predictable revenue streams. Blood Glucose Monitoring continues its transition toward continuous, non-invasive systems, retaining a massive market share due to the global diabetes

Infectious disease POC kits is expected to be the fastest-evolving segment. Post-pandemic infrastructure allows companies to rapidly deploy respiratory, sexually transmitted infection and tropical disease panels. Emerging economies are investing heavily in portable infectious disease screening to address rural healthcare gaps. Cardiometabolic Testing is also gaining traction in the market. As the global population ages, the demand for rapid troponin and BNP tests at the bedside is skyrocketing. Meanwhile, epidemic.

Point-of-Care Diagnostics Market Outlook by Sample Type

• Blood Samples
• Urine Samples
• Saliva Samples
• Nasal and Throat Swab Samples
• Stool Samples
• Tissue and Biopsy Samples

Blood-based POC tests account for the majority share in the point-of-care diagnostics market owing to their relevance across glucose, cardiac markers, coagulation, and infectious disease diagnostics. Technological refinement has significantly reduced sample volume requirements, improving patient comfort and usability. However, there is an aggressive push toward non-invasive samples such as saliva and sweat. Saliva-based diagnostics are gaining traction in infectious disease detection and hormone testing due to their non-invasive nature. Emerging technologies are making saliva-based molecular testing nearly as sensitive as traditional nasal swabs, a development that is drastically improving patient compliance in paediatric and geriatric populations. Urine-based POC tests, especially for pregnancy, kidney function and drug screening, remain key segments.

Point-of-Care Diagnostics Market Outlook by Technology

• Lateral Flow Assay
• Microfluidics
• Biosensor
• Molecular Diagnostics
• Immunoassay

Immunoassay-based platforms currently hold a prominent share in point-of-care diagnostics market owing to cost-effectiveness and broad test availability. Lateral flow assays remain foundational in low-resource settings and low-cost, high-volume sector. Molecular diagnostics, particularly compact PCR systems, represent the fastest-growing technology segment. Although capital-intensive, falling cartridge costs and improved turnaround times are making molecular POC viable even in outpatient clinics.

Biosensor innovations and microfluidic lab-on-chip technologies are emerging disruptors. The miniaturization of PCR and the advent of isothermal amplification (LAMP) have brought lab-grade sensitivity to palm-sized devices. These molecular platforms are achieving the price points necessary for mass adoption in primary care settings.

Point-of-Care Diagnostics Market Outlook by Prescription Type

• Prescription-Based
• Over-The-Counter

Prescription-based POC diagnostics dominate, particularly for cardiac markers, coagulation testing, and infectious diseases requiring medical oversight. Reimbursement structures continue to favour clinician-administered tests. However, over-the-counter (OTC) testing is expanding steadily in point-of-care diagnostics market. Self-testing kits for fertility, infectious diseases and metabolic monitoring are growing in acceptance. Regulatory agencies have shown increased openness toward consumer-accessible diagnostics, especially when supported by digital reporting tools.

Point-of-Care Diagnostics Market Outlook by End User

• Hospitals and Emergency Departments
• Physician Clinics
• Diagnostic Laboratories
• Home Care Settings
• Ambulatory Care Centers
• Military and Field Healthcare Units

Hospitals and emergency departments account for a prominent revenue share in the point-of-care diagnostics market driven by the need for rapid clinical decision-making in acute care. Homecare and self-testing are fast-growing end-user segments, aging populations, remote monitoring programs, and telemedicine integration are fueling demand. Further the integration of POC devices with telehealth platforms has created a feedback loop where the home is becoming a legitimate extension of the clinical lab. By 2033, we expect home-based POC to account for nearly 25% of total market revenue. Retail clinics and pharmacies are also emerging as critical distribution nodes, especially in North America and parts of Europe.

Point-of-Care Diagnostics Market Regional Analysis

Region	Market Share (2025)	Key Market Highlight
North America	44%	Demand remains significant owing to highly sophisticated reimbursement framework and an aggressive push toward decentralized urgent care centers
Europe	27%	Increase in the average age of the population to remain key growth driver
Asia-Pacific	22%	POC diagnostics are not just an alternative to labs, they are the solution to a lack of labs.
Rest of the World	7%	Brazil, GCC Countries, Isreal and Turkey are the major markets

North America remains a prominent region in the point-of-care diagnostics market due to advanced healthcare infrastructure, strong reimbursement frameworks, and aggressive technology adoption. The United States alone represents a substantial share, driven by diabetes prevalence and infectious disease screening initiatives. U.S. remains the global hub for R&D, presence of giants like Danaher and BD ensures a constant pipeline of new technologies.

Europe also a key market supported by universal healthcare coverage and increasing preventive care mandates. Germany, the UK, and France are investing in decentralized testing networks.

Asia-Pacific is the fastest-growing region, fueled by government-led rural healthcare initiatives in India and China. Expanding middle-class populations and urbanization are increasing demand for accessible diagnostics. Latin America and the Middle East & Africa are emerging growth frontiers, particularly for infectious disease POC kits, though infrastructure constraints limit high-end molecular adoption.

Point-of-Care Diagnostics Market Growth Drivers and Opportunities

• Rising chronic disease burden fueling point-of-care diagnostics market growth

Increasing prevalence of diabetes, cardiovascular diseases, respiratory disorders, etc across the globe is driving the point-of-care diagnostics market to a significant extent. Chronic conditions require frequent monitoring, making centralized laboratory testing inefficient. For instance, the International Diabetes Federation estimates that there will be 640 million diabetics globally by 2030. Continuous glucose monitoring adoption, particularly in the U.S. and Western Europe, continues to expand reimbursement coverage.

Shift towards decentralized healthcare systems is also boosting the point-of-care diagnostics market. Payers (insurance companies and governments) have realized that testing a patient at home or in a local pharmacy is cheaper than a diagnostic-related hospital admission. This is pulling the market toward POC solutions. In the UK, the NHS Community Diagnostic Hubs initiative has successfully offloaded 20% of routine lab work to POC-enabled local centers, directly correlating with a reduction in A&E wait times.

• Rural and emerging market penetration creating new market avenues for point-of-care diagnostics market players

Untapped rural populations in Asia and Africa represent a complete white space of the point-of-care diagnostics market players. Governments are investing in portable diagnostic infrastructure to reduce urban healthcare overload. India’s primary healthcare modernization programs and Africa’s infectious disease screening initiatives provide fertile ground for affordable, battery-operated POC devices. Companies capable of delivering robust, low-maintenance devices is expected to gain significant market share.

The ability to perform rapid pharmacogenomic testing at the point of prescription ensuring a patient has the right enzymes to metabolize a specific drug is a substantial opportunity. As personalized medicine moves from the elite research hospital to the general practitioner, demand for companion POC diagnostics to become a requirement for the launch of high-value specialty drugs.

Growth Restraining Factors and Challenges in Point-of-Care Diagnostics Market

• Pricing and reimbursement pressure impacting point-of-care diagnostics market

While innovation accelerates, reimbursement frameworks have not uniformly adapted hindering the point-of-care diagnostics market growth to some extent. Cost-containment measures in public healthcare systems often limit pricing flexibility and in Europe especially, price caps on diagnostic kits restrict premium pricing models. Smaller companies face margin compression unless they achieve scale efficiencies or diversify into higher-margin molecular segments.

The variability in results compared to central laboratory gold standards remains a significant hurdle. Inconsistent calibration across different handheld brands can lead to clinical decisions which creates a liability risk for physicians. A 5% variance in a glucose reading might be manageable, but a similar variance in a high-sensitivity cardiac troponin test can be the difference between a discharge and a life-saving intervention, which is creating challenges in point-of-care diagnostics market.

• Regulatory complexity and quality control are key challenges in point-of-care diagnostics market

Regulatory scrutiny for POC diagnostics has intensified post-pandemic. Authorities are demanding stronger clinical validation and post-market surveillance which is creating challenges for several players in point-of-care diagnostics market. Compliance costs have risen significantly, particularly in the U.S. and EU under updated diagnostic regulations. Smaller innovators face barriers to entry unless supported by strategic partnerships or acquisition by larger players.

As POC devices become IoT-enabled, they become vulnerabilities in a hospital’s cybersecurity. Protecting patient data as it travels from a handheld device over a 5G network to an Electronic Health Record is a technical challenge. Diagnostic companies that do not invest in cybersecurity and data encryption to find themselves excluded from major hospital tenders in the coming years.

Point-of-Care Diagnostics Market Competition Landscape

Competition outlook in point-of-care diagnostics market is somewhat consolidated, dominated by global players such as Abbott, Roche Diagnostics, Siemens Healthineers, Danaher and BD. These companies leverage broad portfolios and global distribution networks, whereas, several mid-sized biotech firms specializing in biosensors were acquired to strengthen innovation pipelines. Key players are also focusing on integrated platforms, subscription-based cartridge models, and data-driven services.

Some of the key players in point-of-care diagnostics market are

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Becton Dickinson (BD)
• Thermo Fisher Scientific
• bioMérieux SA
• QuidelOrtho Corporation
• Hologic, Inc.
• Bio-Rad Laboratories
• Sysmex Corporation
• Werfen
• Nova Biomedical
• EKF Diagnostics Holdings plc.
• Trinity Biotech
• Biosynex Group
• Sekisui Diagnostics
• ACON Laboratories
• SD Biosensor
• Anbio Biotechnology Co., Ltd.

Key Developments in Point-of-Care Diagnostics Market:

• In April 2024, Abbott announced a massive expansion of its i-STAT platform to include a rapid, whole-blood traumatic brain injury (TBI) biomarker, targeting sports medicine and emergency responders.
• In 2024, Roche finalized its acquisition of a leading AI-diagnostics startup to integrate predictive “early-warning” algorithms into its cobas line of POC systems.
• In July 2025, Becton Dickinson (BD) received expanded FDA clearance for its BD Veritor system, allowing for the simultaneous detection of COVID-19, Flu, and RSV in a single OTC kit.
• In June 2025, a strategic partnership between Samsung Healthcare and Danaher was announced to explore the integration of high-resolution mobile imaging with molecular POC data.

Frequently Asked Questions (FAQs) 

1. How point-of-care diagnostics market performing at global level?

The point-of-care diagnostics market is estimated to worth around USD 24.5 billion in 2026 and is projected to reach around USD 36.5 billion by 2033 growing at 5.9% CAGR. Rise in chronic diseases requiring frequent monitoring, combined with healthcare system decentralization is anticipated to remain the major growth drivers for point-of-care diagnostics market.

2. How will the U.S. current landscape affect diagnostic costs?

The emphasis on deregulation and domestic supply chains is expected to lower the cost of regulatory compliance for U.S. based manufacturers leading to a 10-15% reduction in device costs, though increased competition from low-cost emerging market players remains a pressure point.

3. Is Molecular POC (mPOC) really going to replace traditional lab PCR?

While mPOC is superior for rapid, individual decision-making (e.g., in the ER), central labs to always retain the edge in high-throughput, batch testing for population-level screening due to better economies of scale.

4. What is the impact of 5G on the point-of-care diagnostics market?

5G can be considered as nervous system of the market. It enables real-time synchronization of diagnostic data with hospital EHRs without latency, allowing for remote expert interpretation where a specialist in New York can interpret a POC ultrasound performed in rural Montana in real-time.

5. Which segment offers the best ROI for investors through 2033?

Home-based chronic disease management segment is expected to provide a significant ROI for the investors, the transition from episodic testing to continuous monitoring represents a shift from one-time kit sales to recurring, high-margin subscription models for sensors and data analytics.

Take Action Now! Contact us today to access the full report and propel your business forward with cutting-edge insights into the point-of-care diagnostics market.